Project Partners

Fondazione IRCCS Istituto Nazionale dei Tumori

Fondazione IRCCS Istituto Nazionale dei Tumori (INT) is a leading national and international cancer treatment and research centre.  

The Institute addresses clinical challenges across all cancer stages, focusing on: prevention and prediction, diagnosis and treatment (surgery, medicine,radiotherapy), rehabilitation and psychological support, pain management and palliative care. Its mission combines delivering current treatments with pioneering new ones through preclinical, clinical, and data science research, rapid translation of discoveries into improved patient care and quality of life. 

The INT project team includes Dr. Maria Carmen De Santis, Carlotta Giandini, and Maria Grazia Carnevale, radiation oncologists from the Diagnostic Imaging and Radiotherapy, Radiation Oncology Unit; Alessandro Cicchetti, Luca Possenti, Eliana Gioscio, Jacopo Jacovacci, Benedetta Dionisi Ferrera, Francesco Pisani, as multidisciplinary research team, and is supported by Clara Marrone, Daniela Bavuso, and Tania Sanna as coordination team from the Data Science Unit, CMON Lab. 

Under Tiziana Rancati’s leadership as Project Investigator, INT is responsible for Work Package 1 – Coordination and Project Management, which ensures the timely and high-quality delivery of project results through technical, organisational, and financial coordination. WP1 guarantees that project agreements and objectives are correctly implemented, while also overseeing the management of data and knowledge generated throughout the project.  

INT also leads Work Package 9 – Prospective Collection, which establishes a standardised prospective dataset of breast cancer patients receiving radiotherapy after conservative surgery in clinical centres across the TETRIS Consortium. The protocol for the TETRIS prospective observational study.reflects the project’s core vision: integrating biological, clinical, imaging, and behavioral data to improve and enhance digital twins for breast cancer radiotherapy. This new data will support the development of detailed digital twins for radiation safety applications.

In addition, INT coordinates Work Package 10 – Dissemination and Exploitation, which focuses on communicating and promoting project activities and outcomes through targeted dissemination, exploitation, and communication actions addressed to relevant stakeholders : scientific/clinical, industry, regulatory/policy, patient/civil society, and the general public. It also creates synergies with ongoing initiatives and related projects.  

Follow Us

@projectetris
🧩 Inside the TETRIS Consortium

Neolys Diagnostics is a biotechnology company specialised in precision medicine for radiation oncology. Neolys develops innovative medical tests combining DNA repair biomarkers with radiotherapy treatment parameters to anticipate and reduce treatment-related side effects, optimise therapeutic efficacy, and support more personalised radiotherapy strategies.

Within the TETRIS project, Neolys contributes its expertise in functional radiosensitivity testing and oncology innovation under the leadership of Sandrine Pereira, Scientific Director of Neolys Diagnostics.

Neolys leads:
🧪 WP8 – Cellular Sensitivity Testing in the TETRIS Prospective Cohort, focused on assessing cellular radiosensitivity and integrating functional biomarkers with genetic information, including Polygenic Risk Scores (PRS) derived from SNP analysis, to enable multidimensional patient risk profiling.

🔗 Learn more about Neolys Diagnostics and its role in the TETRIS project on our website 🌐 urlr.me/wCdGxf

...

2 0
📢 Thank you for joining the first TETRIS Educational Webinar!

A big thank you to everyone who participated in the first webinar of the TETRIS Educational Webinar Series, delivered by Eva Onjukka and Filippo Schiavo, from Karolinska University Hospital, and moderated by Tiziana Rancati, Project Investigator of the TETRIS project, from Fondazione IRCCS Istituto Nazionale dei Tumori. 

Key takeaways from the webinar:
·  radiation-induced side effects in patients treated with radiotherapy and on how these outcomes are measured using clinician- and patient-reported scales. 
·  importance of evaluating model performance, with a strong emphasis on calibration, crucial for communicating absolute risk to patients, alongside discrimination metrics

🔁 Missed the webinar or would like to watch it again? 
Read the full news on our website here urlr.me/t8nvBQ and access the full recording on TETRIS YouTube channel.

We look forward to welcoming you to the next TETRIS Educational Webinars!

@Karolinska Universitetssjukhuset @karolinskaunivsjukh @istituto_tumori

...

2 0
📢 TETRIS Educational Series. Second Webinar

Following the great participation from our first TETRIS educational webinar, we are pleased to announce that we are ready for the second event of the series.

🗓 Friday, 27 February
⏰ 13:00–14:00 CET

In this second webinar, Claudio Fiorino and Martina Mori from Università Vita-Salute San Raffaele UniSR, will present “Methods for assessing imaging biomarkers in breast cancer radiotherapy within the TETRIS project”
This session will focus on methodological approaches for evaluating imaging biomarkers in breast cancer radiotherapy, highlighting their role within the TETRIS project to support personalised risk assessment and safer treatment pathways. 

👉 To join click here: the session urlr.me/QRzacM.

We look forward to welcoming you to the second appointment of the TETRIS Educational Series. @unisr @Università Vita-Salute San Raffaele @ospedalesanraffaele @IRCCS Ospedale San Raffaele 

Image “Designed by Freepik”, www.freepik.com.

...

1 0